Car T-Cell Therapy

The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

In this video, Jessica Lenzo, MPH, BSN, RN, OCN, discussed how sharing standard operating procedures for the administration of investigational immune effector cell therapy is important.

Although chimeric antigen receptor T-cell therapy is approved for treatment of multiple myeloma, commercially available products are limited to patients who received at least four prior lines of therapy.

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.

May is Brain Cancer Awareness Month.

One of the major complaints of clinicians who treat patients with chimeric antigen receptor T-cell therapies is the time required to produce the highly individualized treatment.

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.

American Society for Transplantation and Cellular Therapy presented awards to three leaders in the fields.

Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.

Younger patients who developed treatment-related hemophagocytic lymphohistiocytosis after tisagenlecleucel infusion for relapsed or refractory B-cell acute lymphoblastic leukemia had significantly poorer outcomes, according to study results.